In the last trading session, 1.01 million PTC Therapeutics Inc (NASDAQ:PTCT) shares changed hands as the company’s beta touched 0.50. With the company’s per share price at $22.17 changed hands at $1.71 or 8.36% during last session, the market valuation stood at $1.67B. PTCT’s last price was a discount, traded about -169.91% off its 52-week high of $59.84. The share price had its 52-week low at $17.53, which suggests the last value was 20.93% up since then. When we look at PTC Therapeutics Inc’s average trading volume, we note the 10-day average is 1.04 million shares, with the 3-month average coming to 1.40 million.
Analysts gave the PTC Therapeutics Inc (PTCT) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.93. If we narrow down to specifics, the data shows that 3 out of 14 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended PTCT as a Hold, 4 felt it is a Buy and 1 rated the stock as Underweight. PTC Therapeutics Inc’s EPS for the current quarter is expected to be $0.31.
PTC Therapeutics Inc (NASDAQ:PTCT) trade information
Instantly PTCT was in green as seen at the end of in last trading. With action 19.64%, the performance over the past five days has been green. The jump to weekly highs of 22.21 on Monday, 11/20/23 added 8.36% to the stock’s daily price. The company’s shares are showing year-to-date downside of -41.92%, with the 5-day performance at 19.64% in the green. However, in the 30-day time frame, PTC Therapeutics Inc (NASDAQ:PTCT) is -4.48% down. Looking at the short shares, we see there were 7.38 million shares sold at short interest cover period of 4.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is $28.08, meaning bulls need an upside of 21.05% from its current market value. According to analyst projections, PTCT’s forecast low is $17.00 with $51.00 as the target high. To hit the forecast high, the stock’s price needs a -130.04% plunge from its current level, while the stock would need to tank 23.32% for it to hit the projected low.
PTC Therapeutics Inc (PTCT) estimates and forecasts
Data shows that the PTC Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.49% over the past 6 months, a 22.72% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for PTC Therapeutics Inc will rise 113.20%, while the growth in revenue is estimated to hit 48.40% for the next quarter. Year-over-year growth is forecast to reach 34.20% up from the last financial year.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of $307.79 million. 5 analysts are of the opinion that PTC Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $187.49 million. The company’s revenue for the corresponding quarters a year ago was $167.41 million and $220.38 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 83.90%. The estimates for the next quarter sales put growth at -14.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -31.05%. The 2023 estimates are for PTC Therapeutics Inc earnings to increase by 25.94%, but the outlook for the next 5-year period is at -9.51% per year.
PTC Therapeutics Inc is expected to release its next quarterly earnings report on October 26.
PTC Therapeutics Inc (NASDAQ:PTCT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.61% of PTC Therapeutics Inc shares while 107.84% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.72%. There are 107.84% institutions holding the PTC Therapeutics Inc stock share, with FMR, LLC the top institutional holder. As of Jun 29, 2023, the company held 13.61% of the shares, roughly 10.25 million PTCT shares worth $416.99 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 10.02% or 7.55 million shares worth $307.16 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 2.32 million shares estimated at $94.41 million under it, the former controlled 3.08% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.54% of the shares, roughly 1.92 million shares worth around $77.9 million.